Please login to the form below

Not currently logged in
Email:
Password:

hepatitis C

This page shows the latest hepatitis C news and features for those working in and with pharma, biotech and healthcare.

Alexion eyes Soliris combo with $930m deal to buy Achillion

Alexion eyes Soliris combo with $930m deal to buy Achillion

Meanwhile, for Achillion the takeover by Alexion marks a renaissance for the company, which had to reinvent itself after a once-promising  hepatitis C virus franchise faded away, taking partner Johnson

Latest news

  • Gilead poaches Genentech-exec Merdad Parsey for its new CMO Gilead poaches Genentech-exec Merdad Parsey for its new CMO

    O’Day has revitalised Gilead since joining the company earlier this year, following a difficult few years as it faces a massive decline in sales of its hepatitis C virus (HCV)

  • Arbutus hit hard as new hep B drug fails on safety Arbutus hit hard as new hep B drug fails on safety

    two cases of acute hepatitis seen in healthy volunteers that thankfully have now resolved. ... With chronic hepatitis C virus (HCV) infections now conquerable using new directly-acting antivirals like Gilead’s Harvoni (sofosbuvir/ledipasvir), the race

  • Sobi set to spend up to $915m to acquire Dova Pharmaceuticals Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

    The drug is in the same class as Novartis’ big earner Promacta/Revolade (eltrombopag) which is used to treat low platelet levels caused by hepatitis C virus infection, as well as

  • GSK to develop Ionis hepatitis B drugs GSK to develop Ionis hepatitis B drugs

    While hepatitis C now has an effective set of treatments which can cure virtually all patients, hepatitis B remains difficult to treat, and can lead to cirrhosis, liver failure and liver ... Gilead is once again setting the pace, and already has a

  • Leiden reassures on key role at Vertex Leiden reassures on key role at Vertex

    The company had been making losses for decades, but had won approval for its oral hepatitis C treatment Incivek (telaprevir) around this time, which became a blockbuster drug for the company.

More from news
Approximately 98 fully matching, plus 260 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 2 fully matching, plus 38 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics